- Home
- TLPH vs SKYE Comparison
TLPH vs SKYE Comparison
Compare TLPH & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLPH | SKYE |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 44.9M |
| IPO Year | 2010 | 2013 |
Fundamental Metrics
Financial Performance| Metric | TLPH | SKYE |
|---|---|---|
| Price | $0.92 | $0.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $6.00 | ★ $14.75 |
| AVG Volume (30 Days) | 227.4K | ★ 260.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 86.41 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,151,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $0.68 |
| 52 Week High | $1.57 | $5.75 |
Technical Indicators
Market Signals| Indicator | TLPH | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 50.60 | 42.72 |
| Support Level | $0.86 | $0.68 |
| Resistance Level | $1.05 | $0.83 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 62.43 | 57.58 |
Price Performance
Historical ComparisonAbout TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.